Showing results (91-100 of 149) with videos related to
Sort By:
Pageof 15
DICP : the Annals of Pharmacotherapy|January 1, 1990
Patterns of neuroleptic usage in continuously hospitalized chronic schizophrenic patients: evidence for development of drug toleranceJ J Sramek, V Gaurano, J M Herrera, et al.The Journal of Clinical Psychiatry|June 1, 1986
Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective studyJ J Sramek, G M Simpson, R L Morrison, et al.Expert Opinion on Investigational Drugs|April 3, 2001
Beta-amyloid therapies in Alzheimer's diseaseS Jhee, T Shiovitz, A W Crawford, et al.European Journal of Clinical Pharmacology|January 1, 1985
Salicylate protein binding in serum from young and elderly subjects as measured by diafiltrationL J Lesko, P K Narang, L Yeager, et al.Clinical Pharmacokinetics|May 1, 2001
Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative reviewS S Jhee, T Shiovitz, A W Crawford, et al.Life Sciences|March 1, 1982
Low-dose apomorphine reduces serum homovanillic acid concentrations in schizophrenic patientsN R Cutler, D V Jeste, F Karoum, et al.Archives of Neurology|February 1, 1986
Cerebrospinal fluid neuron-specific enolase is reduced in Alzheimer's diseaseN R Cutler, A D Kay, P J Marangos, et al.International Journal of Psychosomatics : Official Publication of the International Psychosomatics Institute|January 1, 1991
Adjunctive clonazepam in the treatment of chronic schizophreniaJ M Herrera, W A Alvarez, J P Freinhar, et al.Drug Intelligence & Clinical Pharmacy|March 1, 1988
Pharmacy-based screening program for tardive dyskinesiaT N Ahrens, J J Sramek, J M Herrera, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|July 12, 2002
Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefitEzio Giacobini, R Spiegel, A Enz, et al.Pageof 15